Reimagine Care's CEO says one-off hospital approvals slow CAR-T access and urges buyers to ask vendors to prove outcomes such as avoided ED visits.
|Articles|October 3, 2004
Disease Management Web Exclusive: Breast cancer
Dr. Lesalle Leffall, a cancer specialist, former chairman of the American Cancer Society and current chairman of the Board of the Komen Foundation, influenced former senator and male breast cancer survivor Edward Brooke to go public.
Advertisement
Advertisement
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
The financial pain from your healthcare cost is real, you are uniquely placed to negotiate prices down, and hospitals, at 46% of spending, are where to look, says the CEO and president of the Health Care Cost Institute, which issued its annual cost and utilization report today.
Spending on prescription drugs grew by 40%, faster than spending on inpatient care, outpatient care and professional services, according to a new report from the Health Care Cost Institute.
Meta-analysis links assisted reproduction tech (ART) to higher risks of major heart defects in pregnancies, urging targeted screening and long-term heart health follow-up.
A new Health Care Cost Instittue report finds prices, not utilization, drove spending growth in employer coverage from 2019 to 2023, echoing the group's very first report — and the title of Uwe Reinhardt's famous article.
Reading C-peptide alongside glucose could better predict which autoantibody-positive people will develop type 1 diabetes and detect treatment effects sooner.
Electronic health record developers, health plans, manufacturers and discount programs could support early prescribing decisions by enabling providers and patients to view more pricing options at the point of prescribing, says Joseph Kleiman, president of Buzz Health.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Melanoma care is shifting to risk-based screening and treatment before surgery | Fall Clinical Derm 2026
2
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
3
Experts urge earlier JAK inhibitor use in AD and vitiligo | Fall Clinical Derm 2026
4
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
5